Yang B, Liu D Y, Tian Y, Luo G H, Wang B, Sun Z L
Department of Urology, Affiliated People's Hospital of Guizhou Medical University, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Zhonghua Yi Xue Za Zhi. 2019 Nov 12;99(42):3298-3302. doi: 10.3760/cma.j.issn.0376-2491.2019.42.005.
To study the improvement of lower urinary tract symptoms and related influencing factors in patients with prostate cancer complicated with lower urinary tract symptoms after drugs endocrine therapy. The clinical data of 80 patients with prostate cancer with lower urinary tract symptoms and receiving drug endocrine therapy in Guizhou Provincial People's Hospital from March 2015 to June 2019 were analyzed retrospectively. All patients were followed up, and the mode of administration of the endocrine therapy, the time of administration, and the international prostate symptom score (IPSS2) and quality of life score (QOL2) after treatment were recorded. The improvement of IPSS score and quality of life score after endocrine therapy was observed. The correlation between variance and age, the prostate volume, PSA, tumor stage, Gleason score, symptom severity, medication mode, and medication time were analyzed by variance, chi-square test and paired sample t test. The differences of QOL and IPSS before and after therapy were statistically significant (0.05). Chi-square test found that the effective rate of drug endocrine therapy was not related to age (χ=0.800; 0.371), tumor stage (χ=0.094; 0.759), PSA (χ=0.651; 0.420), prostate volume (χ=0.216; 0.642), Gleason score (χ=0.157; 0.692), symptom severity (χ=0.457; 0.499), medication mode (χ=2.910; 0.233), and medication time (χ=4.159; 0.385). Analysis of variance found that prostate volume and the severity of symptoms was significantly associated with improvement in lower urinary tract symptoms. Drug endocrine therapy can effectively improve the lower urinary tract symptoms of patients with prostate cancer, and the more severe the symptoms and prostate volumeof the patients, the more obvious the improvement of lower urinary tract symptoms. The age, tumor stage, PSA, Gleason score, time and manner of administration were not significantly correlated with improvement in lower urinary tract symptoms.
